Drug-Eluting Stent Features Hydrophilic Coating Technology

The first third-generation drug-eluting stent is now available to physicians and patients in many markets around the world, including countries in Western and Eastern Europe, Asia Pacific and the Middle East. Cordis Corp. expects to offer the CYPHER SELECT Plus Stent in most markets outside the U.S. and Japan within the next two quarters.
In addition to its flexible stent design and short tip, the CYPHER SELECT Plus Stent Delivery System features the CYPH2ONIC Hydrophilic Coating Technology. According to Cordis' lab testing results, this coating is significantly more lubricious than previous sirolimus-eluting stent delivery systems. This combination aims to facilitate the delivery of the stent even when the lesion is located in a tortuous blood vessel.